What is Barigen?
What is Barigen?
Blog Article
Baricitinib is a disease-modifying antirheumatic drug (DMARD) used to improve symptoms and slow the progression of rheumatoid arthritis. In animal models of arthritis, baricitinib has been shown to have significant anti-inflammatory effects while also preserving cartilage and bone without suppressing humoral immunity or causing hematologic side effects. Baricitinib reduces serum immunoglobulin and C-reactive protein levels in patients with rheumatoid arthritis.
Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was subsequently approved by the FDA in 2018. The EC subsequently approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor to be used for this indication in Europe. Although baricitinib was granted emergency use authorization (EUA) for the treatment of COVID-19 in combination with remdesivir in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022.
Barigen is a prescription medicine containing the active ingredient Baricitinib. The ingredients in the medicine include:
Active ingredient: Barigen 4 mg (Baricitinib)
Packaging: box of 30 tablets.
Origin: Bangladesh.
Where to buy Barigen 4mg Baricitinib in Hanoi and Ho Chi Minh City?
Uses of Barigen
Rheumatoid arthritis
Barigen (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors.
Restrictions on use
Should not be used in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with strong immunosuppressants such as azathioprine and cyclosporine.
Coronavirus Disease 2019 (Covid-19)
Barigen is indicated for the treatment of coronavirus disease 2019 (Covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Alopecia areata
Barigen is indicated for the treatment of adult patients with severe alopecia areata.
Restrictions on use
Should not be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.
The mechanism of action of the drug includes:
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cell membrane to influence hematopoiesis and immune cell function. In the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) that regulate intracellular activities including gene expression. Baricitinib modulates the signaling pathway at the JAK site, preventing the phosphorylation and activation of STATs.
JAK enzymes transduce cytokine signals through their coupling (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free enzyme assays, baricitinib was more potent than JAK3 in inhibiting JAK1, JAK2, and TYK2. In human leukocytes, baricitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potency. However, the relationship between inhibition of specific JAK enzymes and therapeutic efficacy is unclear.
Phone: +8801933042721
Email: iebpharma108@gmail.com
Sector 3, Road 8, Uttara-1230 Dhaka, Bangladesh
website: https://iebpharma.com